- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Uncontrolled severe eosinophillic asthma
- Meeting Date: March 2020
- Public Summary Document (PSD) March 2020 PBAC Meeting - (PDF 831KB)
- Public Summary Document (PSD) March 2020 PBAC Meeting - (Word 167KB)
Mepolizumab – March 2020
Mepolizumab: Injection 100 mg in 1 ml pre-filled pen, Injection 100 mg in 1 ml pre-filled syringe; Nucala®
Last updated
3 July 2020